Welcome to our dedicated page for Personalis SEC filings (Ticker: PSNL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Personalis, Inc. filings document regulatory disclosures for a Nasdaq-listed precision oncology genomics company focused on sequencing, data analysis and cancer monitoring tests. Form 8-K reports cover quarterly and annual operating results, clinical test revenue, business highlights, financial guidance and material events involving NeXT Personal and related reimbursement decisions.
The company’s filings also disclose Medicare coverage and rate determinations for NeXT Personal breast and lung cancer surveillance tests, officer appointments and related compensation arrangements, and the registered common stock traded under PSNL. Proxy materials cover board matters, shareholder voting items, executive compensation and governance disclosures for the public company.
Personalis, Inc. CFO and COO Aaron Tachibana exercised stock options and sold shares in a planned transaction. He exercised options for 40,000 shares of common stock at an exercise price of $9.16 per share and then sold 40,000 shares in an open-market transaction at a weighted average price of $12.01 per share, within a range of $12.00 to $12.10. Following these transactions, he holds 198,833 shares of common stock directly and retains 28,832 stock options. The filing states the sales and option exercise were carried out under a Rule 10b5-1 trading plan adopted on August 7, 2025, indicating the trades were pre-arranged.
Aaron L. Tachibana reported mixed transactions involving Common Stock of PSNL. The filing lists 40,000 shares tied to an exercise of stock options dated 06/04/2026 and records prior 10b5-1 sales of 38,799 shares on 05/29/2026 producing $449,273.02. The excerpt also shows a numeric line associating 40,000 shares with $431,200.00 and a figure of 104,721,098 appearing alongside 06/04/2026.
Personalis, Inc. Chief Executive Officer Christopher M. Hall reported an exercise-and-sell transaction in Common Stock under a pre-arranged Rule 10b5-1 trading plan adopted on December 17, 2025. On May 28–29, 2026, he exercised stock options for 100,000 shares at an exercise price of $1.61 per share and sold the same number of shares in open-market transactions at a weighted average price of about $11.02 per share. Following these transactions, he directly holds 235,986 shares of Common Stock and continues to hold stock options covering 300,000 shares of Common Stock.
Personalis, Inc. executive Aaron Tachibana, the CFO and COO, reported an option exercise and related share sale. On May 29, 2026, he exercised stock options to acquire 38,799 shares of Common Stock at an exercise price of $9.16 per share, then sold the same 38,799 shares in open-market transactions at a weighted average price of $11.58 per share, with individual sale prices ranging from $11.50 to $11.71.
The filing notes these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 7, 2025. Following the sale, Tachibana directly holds 198,833 shares of Common Stock and 68,832 stock options that remain outstanding and are fully vested and exercisable, with an expiration date of March 13, 2029.
Personalis, Inc. reported that the Centers for Medicare & Medicaid Services Molecular Diagnostics Program expanded Medicare coverage for its ultrasensitive NeXT Personal test. As of May 19, 2026, coverage now includes monitoring response to neoadjuvant therapy in patients with Stage II–III triple‑negative or HER2‑positive breast cancer.
Personalis, Inc. director Karin Eastham received new equity awards. She was granted 6,250 shares of common stock in the form of restricted stock units and 37,500 stock options with an exercise price of $6.04 per share.
Both the RSUs and options vest 100% on the earlier of the one-year anniversary of the May 12, 2026 grant date or the day before Personalis’ next annual stockholder meeting, subject to continuous service. They also fully vest immediately before a qualifying Change in Control. After these grants, she directly holds 22,366 common shares and 37,500 options.
Personalis, Inc. director Blaine A. Bowman received new equity awards as part of his compensation. He was granted 6,250 restricted stock units, each representing one share of common stock, and 37,500 stock options to buy common shares at an exercise price of $6.04 per share.
The RSUs and options each vest 100% on the earlier of the one-year anniversary of the grant date or the day before the next annual stockholder meeting, contingent on his continuous service under the company’s 2019 Equity Incentive Plan. Both awards fully accelerate and vest immediately before any qualifying Change in Control. Following the RSU grant, Bowman directly holds 19,756 shares of common stock.
Personalis, Inc. director Kenneth J. Widder reported equity awards consisting of restricted stock units and stock options. He was granted 6,250 shares of Common Stock, represented by RSUs that each convert into one share upon settlement, and now holds 6,250 common shares directly after this award.
He also received a stock option for 37,500 shares of Common Stock at an exercise price of $6.04 per share, expiring on May 12, 2036. For both the RSUs and the option, 100% of the shares vest on the earlier of one year from the grant date or the day prior to the next annual stockholders’ meeting, subject to his continuous service. In the event of a Change in Control as defined in the company’s 2019 Equity Incentive Plan, the awards vest in full immediately before that transaction becomes effective.